CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CXCR6 expressing T cells: Functions and role in the control of tumors.
CXCR6 expressing T cells: Functions and role in the control of tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CXCR6是趋化因子CXCL16的受体,CXCL16以膜结合型或可溶型形式存在。CXCR6是组织驻留记忆T(T RM)细胞的标志物,通过与上皮细胞相互作用在免疫监视中发挥作用。CXCR6与表达于肿瘤内某些树突状细胞(DC)亚群(称为DC3)膜上的CXCL16相互作用,使这些CXCR6+ T细胞处于理想位置,以接收同样由DC3呈递的IL-15增殖信号。cxcr6缺陷小鼠或阻断CXCR6与其配体相互作用的小鼠,其CD8+ T细胞对肿瘤增殖的控制能力较差,NKT细胞亦然,尤其在肝脏中。鼻内疫苗接种可诱导肺部CXCL16产生,并与表达CXCR6的T RM浸润相关,而这些T RM是抗肿瘤疫苗发挥疗效所必需的。在治疗方面,将CXCR6加入特异性CAR-T 细胞可增强其在肿瘤内的积聚,并延长胰腺癌、卵巢癌和肺癌动物模型中的生存期。
最后,CXCR6是预测多种癌症中基于抗PD-(L)1免疫治疗应答的免疫学特征之一。相反,CXCR6+ T细胞的促肿瘤作用也有报道,主要见于非酒精性脂肪性肝炎(NASH),其机制为非抗原特异性。靶向并扩增表达CXCR6的抗原特异性T RM及其作为免疫治疗应答生物标志物的潜在用途,为癌症治疗开辟了新前景。
CXCR6 is a receptor for the chemokine CXCL16, which exists as a membrane or soluble form. CXCR6 is a marker for resident memory T (T RM ) cells that plays a role in immunosurveillance through their interaction with epithelial cells. The interaction of CXCR6 with CXCL16 expressed at the membrane of certain subpopulations of intratumor dendritic cells (DC) called DC3, ideally positions these CXCR6 + T cells to receive a proliferation signal from IL-15 also presented by DC3.
Mice deficient in cxcr6 or blocking the interaction of CXCR6 with its ligand, experience a poorer control of tumor proliferation by CD8 + T cells, but also by NKT cells especially in the liver.
Intranasal vaccination induces CXCL16 production in the lungs and is associated with infiltration by T RM expressing CXCR6, which are then required for the efficacy of anti-tumor vaccination. Therapeutically, the addition of CXCR6 to specific CAR-T cells enhances their intratumoral accumulation and prolongs survival in animal models of pancreatic, ovarian and lung cancer.
Finally, CXCR6 is part of immunological signatures that predict response to immunotherapy based on anti-PD-(L)1 in various cancers. In contrast, a protumoral role of CXCR6 + T cells has also been reported mainly in Non-alcoholic steatohepatitis (NASH) due to a non-antigen specific mechanism. The targeting and amplification of antigen-specific T RM expressing CXCR6 and its potential use as a biomarker of response to immunotherapy opens new perspectives in cancer treatment.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。